Patents Assigned to Sloan-Kettering Institute for Cancer Research
  • Publication number: 20220133802
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing immune responses toward tumor and pathogen antigens. It relates to fusion polypeptide that can be expressed in cells (e.g., immunoresponsive cells comprising an antigen-recognizing receptor) to improve the activity and/or efficiency of the cells. In certain embodiments, the fusion polypeptide comprises an extracellular domain and a transmembrane domain of a co-stimulatory ligand, and an intracellular domain of a co-stimulatory molecule.
    Type: Application
    Filed: January 19, 2022
    Publication date: May 5, 2022
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
    Inventors: Michel Sadelain, Mohamad Hamieh, Anton Dobrin
  • Publication number: 20220135564
    Abstract: The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and methods of using the compound to treat pain, depressive disorders, mood disorders, anxiety disorders, opioid use disorder, and opioid withdrawal symptoms.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 5, 2022
    Applicants: The Trustees of Columbia University in the City of New York, The Research Foundation for Mental Hygiene, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Andrew C. Kruegel, Dalibor Sames, Jonathan A. Javitch, Susruta Majumdar
  • Patent number: 11207329
    Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: December 28, 2021
    Assignees: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jimmy Andrew Rotolo, Richard N. Kolesnick, Renata Pasqualini, Wadih Arap
  • Patent number: 11180812
    Abstract: The present invention is directed to methods of diagnosing, prognosing, and monitoring cancer in a subject. These methods involves selecting a subject having cancer, and obtaining, from the selected subject, a sample containing exosomal DNA. The presence or absence of one or more mutations in BRAF and/or EGFR is detected in the exosomal DNA sample from the subject, and a diagnosis and/or prognosis of the cancer is given based on the detection of the one or more mutations in BRAF and/or EGFR. The present invention further relates to methods of treating a subject having cancer and/or monitoring a subject response to therapy based on the detection of one or more mutations in BRAF and/or EGFR in the exosomal DNA sample.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: November 23, 2021
    Assignees: CORNELL UNIVERSITY, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: David C. Lyden, Hector Peinado Selgas, Haiying Zhang, Jacqueline Bromberg
  • Publication number: 20210353607
    Abstract: The development of a new, targeted drug delivery paradigm coupled to improved PI3K inhibitors (e.g., PI3K? inhibitors) represents a significant advance in cancer therapy. Provided herein are compounds, such as compounds of Formula (I) and (II), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The compounds provided herein are PI3K (e.g., PI3K?) inhibitors and are therefore useful for the treatment and/or prevention of various diseases (e.g., proliferative diseases such as cancer). Also provided herein are nanoparticles and nanogels (e.g., P-selectin targeting nanoparticles) comprising PI3K inhibitors, such a compound described herein. In certain embodiments, a nanoparticle or nanogel described herein encapsulates a compound described herein for targeting delivery to cancer cells or tumors.
    Type: Application
    Filed: October 4, 2019
    Publication date: November 18, 2021
    Applicants: Sloan-Kettering Institute for Cancer Research, Tri-lnstitutional Therapeutics Discovery Institute, Inc.
    Inventors: Makoto Fushimi, Maurizio Scaltriti, Daniel Alan Heller, Carles Monterrubio Martinez, Amaia Arruabarrena Aristorena, Peter T. Meinke, Michael Andrew Foley, Yasutomi Asano, Kazuyoshi Aso, Hiroki Takahagi, Yosef Shamay, Jose Manuel Baselga Torres, Yusuke Sasaki, Mayako Michino
  • Publication number: 20210230592
    Abstract: Provided herein are single wall nanotube constructs to which are convalently linked a plurality of a bifunctional chelator, a therapeutic or a diagnostic radionuclide chelated to each bifunctional chelator and a plurality of morpholino oligonucleotides conjugated to the single wall nanotube. Also provided are single wall nanotube complexes which have the morpholino oligonucleotides on the single wall nanotube constructs hybridized to other morpholino oligonucleotides. The other morpholino oligonucleotides are each conjugated to a therapeutic antibody.
    Type: Application
    Filed: January 26, 2021
    Publication date: July 29, 2021
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Michael R. McDevitt, Carlos H. Villa, J. Justin Mulvey
  • Patent number: 11045446
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: June 29, 2021
    Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Publication number: 20210179619
    Abstract: The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with pain, a depressive disorder, a mood disorder or an anxiety disorder by administering the compound to the subject.
    Type: Application
    Filed: February 16, 2021
    Publication date: June 17, 2021
    Applicants: The Trustees of Columbia University in the City of New York, The Research Foundation for Mental Hygiene, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Andrew C. Kruegel, Dalibor Sames, Srijita Bhowmik, Vaclav Havel, Juraj Galeta, Jonathan A. Javitch, Susruta Majumdar
  • Publication number: 20210155899
    Abstract: The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.
    Type: Application
    Filed: November 16, 2020
    Publication date: May 27, 2021
    Applicants: Cornell Research Foundation, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Shahin RAFII, Fan ZHANG, Marco SEANDEL
  • Patent number: 10934271
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: March 2, 2021
    Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute For Cancer Research
    Inventors: Anna Dihas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Patent number: 10919929
    Abstract: The present invention encompasses the recognition that reproducible and detectable changes in the level and or activity of Glucocorticoid Receptor (GR) are associated with incidence and/or risk of Castration Resistant Prostate Cancer (CRPC) and/or doubly resistant prostate cancer, specifically in individuals having prostate cancer and on antiandrogen therapy, and provides for the use of GR inhibitors to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer. In some embodiments, GR inhibitors also have Androgen Receptor (AR) inhibitory activity or are administered in conjunction with AR inhibitors. The present invention also provides technologies for identification and/or characterization of agents to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer; in some embodiments such agents alter level and/or activity of a GR. In some embodiments, provided agents show effects on a GR's activity of regulating transcription of one or more target genes.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: February 16, 2021
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Vivek Arora, Charles L. Sawyers, Michael J. Evans, Darren R. Veach
  • Patent number: 10865379
    Abstract: The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: December 15, 2020
    Assignees: Cornell Research Foundation, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Shahin Rafii, Fan Zhang, Marco Seandel
  • Patent number: 10844436
    Abstract: The present invention is directed to methods of prognosing, treating, or managing treatment of cancer in a subject. These methods involve selecting a subject having cancer, obtaining, from the selected subject, a sample containing exosomes, recovering the exosomes from the sample, and isolating the double-stranded DNA from within the exosomes. The isolated double-stranded DNA is then used to detect the presence or absence of one or more genetic mutations associated with cancer, quantify the amount of isolated double-stranded DNA from the recovered exosomes in the sample, detect the methylation status of the isolated double-stranded DNA, or quantify the amount isolated double-stranded DNA able to enter a recipient cell. The prognosing, treating, or managing treatment is carried out based on this information.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: November 24, 2020
    Assignees: CORNELL UNIVERSITY, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: David C. Lyden, Hector Peinado Selgas, Haiying Zhang, Basant Kumar Thakur, Annette Becker, Jacqueline Bromberg
  • Patent number: 10820986
    Abstract: An ocular prosthesis includes a display device visible at an anterior portion of the ocular prosthesis. The display device is configured to present a changeable image that represents a natural appearance and movement for a visible portion of an eyeball of a subject. A system includes, besides the ocular prosthesis, an implant marker configured to move with an orbital implant disposed in an eye socket of a subject. A method includes determining a change in orientation of an orbital implant in a subject and determining an update to a natural appearance for a visible portion of an eyeball for the subject based on the change in orientation of the orbital implant. The method also includes rendering an update to an image of the natural appearance for a display device disposed in an ocular prosthesis configured to be inserted in the subject anterior to the orbital implant.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: November 3, 2020
    Assignee: Sloan Kettering Institute for Cancer Research
    Inventors: David Abramson, George C. Bohle, III, Paul Frisch, Brian P. Marr, Paul Booth, Philip C. Black, Alan B. Katze, James G. Moore
  • Patent number: 10766875
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: September 8, 2020
    Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Anna Dihas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Patent number: 10722577
    Abstract: It has been discovered that administering therapeutically effective amounts of an antibiotic that kills Gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTL)-induced killing and/or by damage to endothelial microvasculature, including Radiation GI syndrome, GvHD disease, inflammatory diseases and autoimmune diseases.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: July 28, 2020
    Assignee: Sloan Kettering Institute for Cancer Research
    Inventors: Jimmy Andrew Rotolo, Richard N. Kolesnick
  • Patent number: 10676476
    Abstract: Purine scaffold Hsp90 inhibitors are useful in therapeutic applications and as radioimaging ligands.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: June 9, 2020
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Gabriela Chiosis, Huazhong He, Laura Llauger-Bufi, Joungnam Kim, Steven M. Larson, Peter Smith-Jones
  • Publication number: 20200061196
    Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.
    Type: Application
    Filed: September 9, 2019
    Publication date: February 27, 2020
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
  • Patent number: 10556882
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: February 11, 2020
    Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute For Cancer Research
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Patent number: 10548997
    Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: February 4, 2020
    Assignees: Sloan-Kettering Institute for Cancer Research, Cornell University
    Inventors: Michelle S. Bradbury, Ulrich Wiesner, Oula Penate Medina, Hooisweng Ow, Andrew Burns, Jason S. Lewis, Steven M. Larson